Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma.

Saved in:
Bibliographic Details
Title: Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma.
Authors: Ding R; Department of Minimally Invasive Intervention, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China.; Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.; Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China., Bai JF; Department of Minimally Invasive Intervention, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China., Jin ZC; Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.; Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China., Xiao YD; Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.; Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China.; Department of Radiology, The Second Xiangya Hospital of Central South University, Hunan, China., Chen JJ; Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.; Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China.; Department of Interventional Radiology, Sichuan Cancer Hospital and Institute, Chengdu, China., Zhu XL; Department of Interventional Radiology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, China., Xin YJ; Department of Minimally Invasive Comprehensive Treatment of Cancer, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China., Chen JZ; State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China., Tie J; National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi'an, China., Zhu KS; Department of Minimally Invasive Interventional Radiology and Radiology Center, and Minimally Invasive and Interventional Cancer Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., Zhang L; Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China., Shi HB; Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Liu RB; Department of Interventional Radiology, The Tumor Hospital of Harbin Medical University, Harbin, China., Xu AB; Department of Interventional Therapy, Nantong Tumor Hospital, Nantong, China., Ji F; Department of Hepatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.; Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Ministry of Education of China, Xi'an, China., Huang MS; Department of Interventional Radiology, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China., Ji JS; Department of Radiology, Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, School of Medicine, Lishui Hospital of Zhejiang University, Lishui, China., Yuan CW; Center of Interventional Oncology and Liver Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China., Yang WZ; Department of Interventional Radiology, Union Hospital of Fujian Medical University, Fuzhou, China., Xu GH; Department of Interventional Radiology, Sichuan Cancer Hospital and Institute, Chengdu, China., Tu Q; Department of Hepatobiliary Oncology Surgery, Department of Interventional Oncology, Jiangxi Cancer Hospital of Nanchang University, Nanchang, China., Jiang H; Cancer Treatment Centers, Second Affiliated Hospital of Kunming Medical University, Kunming, China., Shao HB; Department of Interventional Radiology, The First Hospital of China Medical University, Shenyang, China., Shi BQ; Department of Intervention, Inner Mongolia People's Hospital, Hohhot, China., Huang M; Department of Minimally Invasive Intervention, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China., Zhong BY; Department of Interventional Radiology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China., Zhu HD; Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.; Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China., Ren ZG; Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China., Teng GJ; Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.; Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China.
Source: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2026 Jun; Vol. 63 (12), pp. 1617-1625. Date of Electronic Publication: 2026 Mar 31.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1365-2036
DOI:10.1111/apt.70612